XBIOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.56 USD | +3.01% |
|
-8.74% | +114.00% |
| Mar. 15 | XBiotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 04 | XBiotech Inc. to Begin Constructing New R&D Facility on Its 48-Acre Campus | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 182 | 766.9 | 457.9 | 338.3 | 106.8 | 121.7 |
| Enterprise Value (EV) 1 | 166.1 | 52.29 | 220.6 | 101.4 | -110.6 | -78.28 |
| P/E ratio | -8.6 x | 1.29 x | -43 x | -19.2 x | -3.25 x | -4.94 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 10,408,178 x | 18,394,276 x | 26,643,856 x | - |
| EV / Revenue | - | - | 5,013,128 x | 5,510,564 x | -27,590,059 x | - |
| EV / EBITDA | -8.95 x | -1.81 x | -13.8 x | -4.52 x | 3.47 x | 2.19 x |
| EV / FCF | -19.3 x | 1.22 x | -1.54 x | 1.54 x | 17.5 x | 4.86 x |
| FCF Yield | -5.19% | 81.8% | -65% | 65.1% | 5.72% | 20.6% |
| Price to Book | 4.41 x | 1.03 x | 1.32 x | 1.26 x | 0.44 x | 0.56 x |
| Nbr of stocks (in thousands) | 35,820 | 41,087 | 29,261 | 30,399 | 30,439 | 30,437 |
| Reference price 2 | 5.080 | 18.66 | 15.65 | 11.13 | 3.510 | 4.000 |
| Announcement Date | 3/14/19 | 3/16/20 | 3/16/21 | 3/15/22 | 3/15/23 | 3/15/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 44 | 18.39 | 4.01 | - |
| EBITDA 1 | -18.56 | -28.87 | -16.04 | -22.43 | -31.88 | -35.77 |
| EBIT 1 | -20.99 | -31.23 | -18.28 | -25.08 | -34.49 | -37.51 |
| Operating Margin | - | - | -41.54% | -136.36% | -860.1% | - |
| Earnings before Tax (EBT) 1 | -21.14 | 718.5 | -12.83 | -25.46 | -33.59 | -24.31 |
| Net income 1 | -21.14 | 668.6 | -11.22 | -17.41 | -32.9 | -24.56 |
| Net margin | - | - | -25.5% | -94.67% | -820.45% | - |
| EPS 2 | -0.5904 | 14.44 | -0.3640 | -0.5800 | -1.081 | -0.8100 |
| Free Cash Flow 1 | -8.627 | 42.76 | -143.4 | 66 | -6.33 | -16.1 |
| FCF margin | - | - | -325.88% | 358.82% | -157.86% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 6.4% | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/14/19 | 3/16/20 | 3/16/21 | 3/15/22 | 3/15/23 | 3/15/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 15.8 | 715 | 237 | 237 | 217 | 200 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -8.63 | 42.8 | -143 | 66 | -6.33 | -16.1 |
| ROE (net income / shareholders' equity) | -41.6% | 168% | -2.03% | -5.64% | -12.9% | -10.7% |
| ROA (Net income/ Total Assets) | -24.5% | -4.53% | -1.95% | -4.99% | -8.27% | -9.92% |
| Assets 1 | 86.44 | -14,750 | 575 | 349.3 | 397.8 | 247.6 |
| Book Value Per Share 2 | 1.150 | 18.20 | 11.90 | 8.850 | 7.900 | 7.190 |
| Cash Flow per Share 2 | 0.4400 | 17.20 | 8.100 | 7.790 | 5.170 | 6.570 |
| Capex 1 | 0.12 | 0.2 | 3.73 | 3.53 | 0.59 | 0.36 |
| Capex / Sales | - | - | 8.47% | 19.16% | 14.59% | - |
| Announcement Date | 3/14/19 | 3/16/20 | 3/16/21 | 3/15/22 | 3/15/23 | 3/15/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +114.00% | 253M | |
| +5.66% | 109B | |
| +11.23% | 105B | |
| -0.38% | 22.25B | |
| -12.15% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.09% | 16.85B | |
| +3.33% | 13.76B | |
| +36.58% | 12.46B |
- Stock Market
- Equities
- XBIT Stock
- Financials XBiotech Inc.